May 2, 2019, MedPage Today 

Dropping chemotherapy from a first-line regimen of trastuzumab (Herceptin) and pertuzumab (Perjeta) didn't compromise overall survival at 2 years in advanced HER2-positive breast cancer, although disease progression resumed much faster, a randomized phase II trial found. 

Read more.